NCT04505501View on ClinicalTrials.gov

Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV Infection

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
HIV/AIDS
Interventions
DRUG

N-803

N-803 is a novel IL-15 superagonist complex that enhances NK cell and CD8+ T-cell proliferation and activation.

Trial Locations (1)

10330

Thai Red Cross AIDS Research Centre, Bangkok

All Listed Sponsors
collaborator

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

Thai Red Cross AIDS Research Centre

OTHER